Influenza, an ever-evolving target for vaccine development
It's that time of year again. Coughing coworkers, student absences, and reminders to get your shot are sure signs that flu season is upon us. This year's epidemic seems to have struck earlier and harder than usual all amid concerns over shortages of the flu vaccine. While some vaccines provide lifelong protection with one or a few doses (e.g., measles, mumps, and polio), the flu requires a new shot every year. And in some years, the flu shot is hardly effective at all. Why is the flu vaccine different from so many other vaccines? A look at the evolution of the flu virus can explain the weaknesses of current vaccines and points the way towards a vaccine that could provide long-lasting, universal protection.
Where's the evolution?
In fact, in a process called antigenic drift, flu evolves in response to the antibodies our bodies produce each year. During the course of a flu epidemic, many people gain immunity to the strain of the virus that is currently circulating. Through the process of natural selection, any flu virus particles that happen to carry mutations that allow them to slip by the defenses of common antibodies will be favored, produce more copies of themselves, and eventually, spread to more new victims. This process leads to the evolution of new strains, one or some of which are likely to become the cause of next year's flu season.
Each year's flu vaccine is actually a cocktail of vaccines for a few different flu strains (generally three) that World Health Organization scientists predict will spread during that year's flu season. Usually, the predictions match the most common strains closely enough that the vaccine ends up being fairly effective. (This year's vaccine provides about 60% increased protection for those who are vaccinated.) Very occasionally, however, the most common strains are unexpected ones, and getting a flu shot does little to stave off the disease.
Now, many researchers think that a new approach to the flu vaccine could make it more consistently effective and alleviate the need to get a shot every year. Current vaccines produce antibodies that recognize a protein on the outer coating of the virus called hemagglutinen, and they focus on a particular part of that molecule, the "head" region. The head of hemagglutinen is good at stimulating the production of protective antibodies, but it is also the part of the virus that is most susceptible to antigenic drift. What if researchers could build a vaccine that targeted a part of the flu virus that evolves more slowly?
Different traits evolve at different rates. For example, traits experiencing strong selection favoring a form different than the current form (as is the case with the head of influenza's hemagglutinen protein) evolve quickly, while key traits that can't change much without compromising the functioning of the organism tend to evolve slowly. Slow evolving traits are called evolutionarily conserved traits. It's easy to understand why very important and finely tuned traits would be conserved. For example, many of the genes that are responsible for laying out the basic body patterns of animals are highly conserved over tens of millions of years of evolutionary history because most mutations to these genes have effects that are incompatible with life and are not passed on.
Many scientists suspect that highly conserved molecules in the flu virus could be used as the basis of a universal flu vaccine that wouldn't need to be reformulated (and re-received!) every year. A few proteins hold particular promise. First, though the head of hemagglutinen evolves at lightening speed, certain parts of the hemagglutinen stem (the part that connects to the viral membrane and which helps the virus invade cells in the respiratory tract) are nearly identical across a wide range of flu strains. Another relatively invariable protein found in the viral membrane is called M2. It helps control the pH inside virus particles, allowing them to release their RNA into the host cell and take it over. Neuraminidase (shown in the diagram above) helps newly produced viruses break out of a host cell and also varies little from flu virus to flu virus. One of these slow-evolving molecules might make an ideal target for a flu vaccine that protects against a diversity of viral strains.
The days of a yearly flu shot may be numbered. Researchers are pursuing several different approaches to a vastly improved flu vaccine. As described here, some are focused on building vaccines based on evolutionarily conserved regions of the virus; however, others are working on new ways of making the vaccine on short notice, and still others are working on tweaks to existing flu vaccines that would help our bodies mount a stronger defense against the virus. Though the new research holds promise, it will require many years of additional study before new-and-improved vaccines can be established as safe and effective and brought to market. Until then, the Centers for Disease Control and Prevention recommend that you get your yearly flu shot. It's not perfect, but it's still the best way to reduce your odds of spending a feverish, achy week with a box of tissues in your lap!
Discussion and extension questions
View this article online at:
Understanding Evolution © 2017 by The University of California Museum of Paleontology, Berkeley, and the Regents of the University of California